Biphenylhexanol | 1026101-73-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Biphenylhexanol
• 英文别名: 6-(2-phenylphenyl)hexan-1-ol
• CAS: 1026101-73-4
• 化学式: C₁₈H₂₂O
• 分子量: 254.372
• InChiKey: FQTSAORYAAPPOG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.9
• 重原子数：
  19
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Biphenylhexanol 在 potassium dihydrogenphosphate 、 N-溴代丁二酰亚胺(NBS) 、 sodium methylate 、 三苯基膦 作用下， 以 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.59h， 生成 Methyl 3-cyano-3-hydroxy-4-[6-(2-phenylphenyl)hexylsulfanyl]butanoate
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme

  摘要：

  ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of a-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme, The best compounds, 58, 68, 71, 74 have reversible K-i's in the 1-3 mu M range against the isolated rat enzyme, As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP-citrate lyase.

  DOI：

  10.1021/jm960167w
• 作为产物：
  描述：

  4-羧丁基三苯基溴化膦 在 platinum(IV) oxide 氢气 、 二异丁基氢化铝 、 dimsyl sodium 作用下， 以 甲醇 、 乙醚 、 二氯甲烷 为溶剂， 25.0 ℃ 、344.73 kPa 条件下， 反应 2.0h， 生成 Biphenylhexanol
  参考文献：
  名称：

  ATP-Citrate Lyase as a Target for Hypolipidemic Intervention. Design and Synthesis of 2-Substituted Butanedioic Acids as Novel, Potent Inhibitors of the Enzyme

  摘要：

  ATP-citrate lyase is the primary enzyme responsible for the synthesis of cytosolic acetyl-CoA in many tissues. Inhibitors of the enzyme represent a potentially novel class of hypolipidemic agent, which are anticipated to have combined hypocholesterolemic and hypotriglyceridemic properties. A series of a-substituted butanedioic acids have been designed and synthesized as inhibitors of the enzyme, The best compounds, 58, 68, 71, 74 have reversible K-i's in the 1-3 mu M range against the isolated rat enzyme, As representative of this compound class, 58, has been shown to exert its inhibitory action through a mainly competitive mechanism with respect to citrate and a noncompetitive one with respect to CoA. None of the inhibitors were able to inhibit cholesterol and/or fatty acid synthesis in HepG2 cells. This has been attributed to the adverse physicochemical properties of the molecules leading to a lack of cell penetration. Despite this, a lead structural class of compound has been identified with the potential for modification into potent, cell-penetrant, and efficacious inhibitors of ATP-citrate lyase.

  DOI：

  10.1021/jm960167w

文献信息

• Alpha-phosphorous substituted sulfonate derivatives as squalene synthetase inhibitors
  申请人：E.R. Squibb & Sons, Inc.

  公开号：EP0595635A1

  公开（公告）日：1994-05-04

  α-Phosphonosulfonate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These comounds have the formula wherein R² is OR⁵ or R5a; R³ and R⁵ are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R5a is H, alkyl, arylalkyl or aryl; R4 is H, alkyl, aryl, arylalkyl, or cycloalkyl;, Z is H, halogen, lower alkyl or lower alkenyl; and R¹ is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts and or prodrug esters of the phosphonic (phosphinic) and/or sulfonic acids.

  提供了α-磷酸磺酸酯化合物，可抑制齿烷合酶酶并从而抑制胆固醇生物合成。这些化合物的化学式为：其中R²是OR⁵或R5a; R³和R⁵独立地为H，烷基，芳基烷基，芳基或环烷基; R5a为H，烷基，芳基烷基或芳基; R4为H，烷基，芳基，芳基烷基或环烷基; Z为H，卤素，低烷基或低烯基; R¹为至少含有7个碳的疏水基团，为烷基，烯基，炔基，混合烯基-炔基，芳基，芳基烷基，环烷基，环烷基烷基，杂环芳基，杂环芳基烷基，环杂芳基烷基，环杂芳基烷基烷基; 包括磷酸（磷酸酯）和/或磺酸的药物可接受盐和/或前药酯。
• Methods of using .alpha.-phosphonosulfonate squalene synthetase
  申请人：Bristol-Myers Squibb Company

  公开号：US05470845A1

  公开（公告）日：1995-11-28

  .alpha.-Phosphonosulfonate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula ##STR1## wherein R.sup.2 is OR.sup.5 or R.sup.5a ; R.sup.3 and R.sup.5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R.sup.5a is H, alkyl, arylalkyl or aryl; R.sup.4 is H, alkyl, aryl, arylalkyl, or cycloalkyl;, Z is H, halogen, lower alkyl or lower alkenyl; and R.sup.1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts and or prodrug esters of the phosphonic (phosphinic) and/or sulfonic acids.

  提供了α-磷酸磺酸酯化合物，可抑制齿烯合酶酶，并从而抑制胆固醇生物合成。这些化合物具有以下式子：##STR1##其中，R.sup.2为OR.sup.5或R.sup.5a；R.sup.3和R.sup.5独立地为H、烷基、芳基烷基、芳基或环烷基；R.sup.5a为H、烷基、芳基烷基或芳基；R.sup.4为H、烷基、芳基、芳基烷基或环烷基；Z为H、卤素、低级烷基或低级烯基；R.sup.1为至少含有7个碳的亲脂性基团，为烷基、烯基、炔基、混合烯基-炔基、芳基、芳基烷基、环烷基、环烷基烷基、杂芳基、杂芳基烷基、环杂烷基或环杂烷基烷基；包括所述的药学上可接受的磷酸（磷酸酸）和/或磺酸的前药酯盐。
• .alpha.-phosphonosulfonate squalene synthetase inhibitors
  申请人：——

  公开号：US05712396A1

  公开（公告）日：1998-01-27

  .alpha.-Phosphonosulfonate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula ##STR1## wherein R.sup.2 is OR.sup.5 or R.sup.5a ; R.sup.3 and R.sup.5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R.sup.5a is H, alkyl, arylalkyl or aryl; R4 is H, alkyl, aryl, arylalkyl, or cycloalkyl;, Z is H, halogen, lower alkyl or lower alkenyl; and R.sup.1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts and or prodrug esters of the phosphonic (phosphinic) and/or sulfonic acids.

  提供了抑制齿烯合成酶并从而抑制胆固醇生物合成的.alpha.-磷酸磺酸盐化合物。这些化合物的化学式为##STR1##其中R.sup.2为OR.sup.5或R.sup.5a; R.sup.3和R.sup.5分别为H、烷基、芳基烷基、芳基或环烷基；R.sup.5a为H、烷基、芳基烷基或芳基；R4为H、烷基、芳基、芳基烷基或环烷基；Z为H、卤素、低烷基或低烯基；R.sup.1为至少含有7个碳的脂溶性基团，可以是烷基、烯基、炔基、混合烯基-炔基、芳基、芳基烷基、环烷基、环烷基烷基、杂芳基、杂芳基烷基、环杂基、环杂基烷基；还包括上述定义的磷酸（亚磷酸）和/或磺酸的药学上可接受的盐和/或前药酯。
• .alpha.-phosphonosulfonate squalene synthetase inhibitors and method
  申请人：Bristol-Myers Squibb Company

  公开号：US05567841A1

  公开（公告）日：1996-10-22

  .alpha.-Phosphonosulfonate compounds are provided which inhibit the enzyme squalene synthetase and thereby inhibit cholesterol biosynthesis. These compounds have the formula ##STR1## wherein R.sup.2 is OR.sup.5 or R.sup.5a ; R.sup.3 and R.sup.5 are independently H, alkyl, arylalkyl, aryl or cycloalkyl; R.sup.5a is H, alkyl, arylalkyl or aryl; R.sup.4 is H, alkyl, aryl, arylalkyl, or cycloalkyl;, Z is H, halogen, lower alkyl or lower alkenyl; and R.sup.1 is a lipophilic group which contains at least 7 carbons and is alkyl, alkenyl, alkynyl, mixed alkenyl-alkynyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, cycloheteroalkyl, cycloheteroalkylalkyl; as further defined above; including pharmaceutically acceptable salts and or prodrug esters of the phosphonic (phosphinic) and/or sulfonic acids.

  提供了α-磷酸磺酸化合物，可以抑制齿烯合酶酶并从而抑制胆固醇生物合成。这些化合物的化学式为##STR1##其中R.sup.2是OR.sup.5或R.sup.5a;R.sup.3和R.sup.5分别是H、烷基、芳基烷基、芳基或环烷基；R.sup.5a是H、烷基、芳基烷基或芳基；R.sup.4是H、烷基、芳基、芳基烷基或环烷基；Z是H、卤素、低烷基或低烯基；R.sup.1是至少含有7个碳的亲脂性基团，可以是烷基、烯基、炔基、混合烯炔基、芳基、芳基烷基、环烷基、环烷基烷基、杂芳基、杂芳基烷基、环杂烷基、环杂烷基烷基等，包括磷酸（亚磷酸）和/或磺酸的药物可接受的盐和/或前药酯。
• US5470845A
  申请人：——

  公开号：US5470845A

  公开（公告）日：1995-11-28